Rare Partners srl Impresa Sociale Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2019
NCT03877809
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Rare Partners srl Impresa Sociale

Active Ingredients

Drugs in Phase 2 Trials (1)

sirolimus (rapamune) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

beta-Thalassemia (Phase 2)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1